Xeptiva Therapeutics

  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trials
    • Chronic Pain
    • Atopic Dermatitis
  • News
    • See news
    • Press
  • Blog
  • Contact
  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trials
    • Chronic Pain
    • Atopic Dermatitis
  • News
    • See news
    • Press
  • Blog
  • Contact

CELEBRATING EXCELLENCE: Dr. LUIS BARBEITO WINS THE NATIONAL SCIENCE GRAND PRICE 2024

DECEMBER, 2024
read below
Picture

​
​Dr. Luis Barbeito, our CIO, is the winner of the second edition of the National Science Grand Prize 2024. This prestigious recognition, awarded by the Ministry of Education and Culture, highlights the scientific work of Uruguayan researchers and emphasizes Luis's commitment and dedication to innovation and the advancement of knowledge in our country.
​
Dr. Luis Barbeito is recognized as one of the best scientists in Uruguay. A graduate of the Faculty of Medicine at the University of the Republic in 1982, his career in neuroscience began as an assistant in the Department of Histology and Embryology. Throughout his career, he has held key roles in prestigious institutions, including the Institut Pasteur de Montevideo, where he excelled as scientific and executive director.

​His background in neuroscience and dedication to research have laid a solid foundation for the development of new therapies and approaches in the treatment of neurodegenerative diseases. This recognition not only celebrates his individual achievements but also his contribution to strengthening the Uruguayan scientific community.
​
At Xeptiva, we are proud to have Dr. Barbeito on our team. As co-founder and creator of Xeptiva's technology, his work is a true example of excellence and dedication, fundamental to the success of our research and development projects.
​

COMPANY

About Us
Team

INNOVATION

Technology
Pipeline
Target diseases

clinical trial

NEWS

See News
Press releases

cONTACT

BLOG

© COPYRIGHT 2025.  ALL RIGHTS RESERVED.